Revvity Expands Metabolic Disease Drug Discovery with Human Cell Design Acquisition — Revvity, Inc.

Event summary

Revvity to acquire Human Cell Design (HCD), a France-based biotech specializing in human cell models for metabolic diseases.
HCD’s EndoC-βH5 human pancreatic beta cell model will be integrated into Revvity’s Life Sciences portfolio.
Transaction expected to close in Q4 2026, subject to regulatory approvals.
HCD’s NatLine platform supports development of functionally consistent human cell models.

The big picture

Revvity’s acquisition of Human Cell Design aligns with the broader industry trend towards human-relevant cell models for drug discovery, particularly in metabolic diseases like diabetes and obesity. This move strengthens Revvity’s position in the Life Sciences sector, providing it with a competitive edge in offering integrated solutions for drug screening and preclinical research. With 2025 revenue of $2.9 billion, Revvity is positioning itself to capitalize on the growing demand for advanced cellular models in therapeutic research and development.

What we're watching

Integration Challenges: How Revvity will integrate HCD’s technology into its existing portfolio and whether it can maintain HCD’s specialized capabilities.
Market Expansion: The pace at which Revvity can leverage HCD’s human-relevant cell models to capture a larger share of the metabolic disease drug discovery market.
Regulatory Approvals: Whether the acquisition will face any regulatory hurdles that could delay or complicate the closing of the deal.